Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 3Malignant Female Reproductive System Neoplasm 2Rectal Neoplasms 1Pulmonary Nodule 1Pain, Postoperative 1Neoplasms 1Ileus 1Hematologic Neoplasms 1Emergencies 1Diverticulosis, Colonic 1Diverticulitis, Colonic 1Constipation 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Cancer Pain 1Agnosia 1

Interventions

Dexamethasone 8Oxycodone 6Epoetin Alfa 5Propofol 4Palonosetron 4Meropenem 4Zoledronic Acid 3Vancomycin 3Sevoflurane 3Ondansetron 3Naloxone 3Everolimus 3Ciprofloxacin 3Cholecalciferol 3Ceftazidime 3Cefepime 3Calcium Dobesilate 3Bevacizumab 3Aspirin 3Aprepitant 3peginterferon alfa-2a 2edoxaban 2apixaban 2apatinib 2Vitamin B 12 2Vincristine 2Tobacco Use Cessation Devices 2Teicoplanin 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms × Hydromorphone × Clear all
NCT01648699 2013-10-11

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Janssen Pharmaceutica

Phase 4 Terminated
20 enrolled 9 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡